Healthcare Professionals

Osteoarthritis Epidemiology

Most common form of arthritis¹

Osteoarthritis (OA) affects 7% of the global population²

Leading cause of disability in older adults

OA related joint pain can cause functional limitations such as loss of independence, fatigue, low mood and poor sleep¹

Common reason for consultation in general practice

1/3 of adults aged 45 years and over have sought treatment for OA³

Classical treatments focus on symptom relief and not root cause

Of which many have associated side effects⁴

The Gut Microbiota and Osteoarthritis

In addition to mechanical and other risk factors, accumulating evidence suggests that the presence of chronic low-grade inflammation has a role in the development of osteoarthritis. This low-grade inflammation appears to be related to the composition of the gut microbiota¹¹.

An imbalance of the gut microbiota, known as dysbiosis, can lead to increased permeability of the intestinal wall. This facilitates the movements of pro-inflammatory molecules such as endotoxins into the blood. These endotoxins can activate the immune system and cause systemic low-grade inflammation, which may ultimately lead to breakdown of the joint structure5 6 7.

Osteoarthritis and the microbiome

Microbial dysbiosis has recently emerged as an important pathogenic factor in the initiation and progression of osteoarthritis5

The link between dysbiosis and osteoarthritis offers new therapeutic opportunities to help patients manage the condition. By modulating the composition of the gut bacteria it may be possible to reduce the progression of osteoarthritis5.

† Dysbiosis: Adverse alterations in the diversity, structure or function of gut microbiota that is associated with disease

Bifidobacterium longum CBi0703:

A Microbiotic Innovation in Osteoarthritis

Preclinical Data

Preclinical model of primary osteoarthritis9
  • Control group: received H20
  • Intervention group: received inactivated culture of Bifidobacterium Longum  CBi0703

Results: % of moderate to severe osteoarthritis

CONCLUSION - CBi0703 reduced cartilage structural lesions and cartilage degradation markers, providing an overall joint protective effect.

User Study: Evaluation of therapeutic satisfaction of the product10
(Bifidobacterium Longum CBi0703 + Vitamin C)

3 month 
 user study

320 male and females with mild-moderate osteoarthritis

1 capsule/day (Bifidobacterium longum CBi0703 + Vitamin C)

Outcome Measures

Frequency of flare up

Duration of flare up

Pain Intensity

(Visual Analogue Scale (VAS))

Analgesic/ NSAID use

CONCLUSION - The combination of Bifidobacterium Longum CBi0703 + Vitamin C reduced the frequency, duration and intenstiy of painful flare ups in patients with OA and reduced the consumption of pain and anti-inflammatory medication

For more information or to stock contacts us


  1. Hawker GA (2019) Clinical and Experimental Rheumatology 120(5), 3-6.
  2. Hunter DJ et al. (2020) The Lancet 396, 1711-1712
  3. Arthritis Research UK (2013) Osteoarthritis in general practice.
  4. Reijman M et al. (2005) Arthritis and Rheumatism 52(10), 3137-3142
  5. Favazzo LJ et al. (2020) Current Opinion in Rheumatology 32(1), 92-101
  6. Huang Z et al. (2016) Nature Reviews Rheumatology 12(2), 123-129
  7. Hao X et al. (2021) Arthritis Research and Therapy 23(42)
  8. Romond MB et al. (2008) Anaerobe 14(1), 43-48
  9. Henrotin Y et al. (2019) Cartilage. doi: 10.1177/1947603519841674
  10. Internal data
  11. Chisari E et al. (2021) PLoS ONE 16(12).
Important Notice: This page is inteded for Healthcare Professionals. By clicking to enter, you are confirming that you are a Healthcare Professional.